Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasmablast | 5 studies | 32% ± 17% | |
| erythrocyte | 5 studies | 29% ± 13% | |
| transit amplifying cell | 4 studies | 24% ± 1% | |
| plasma cell | 4 studies | 24% ± 4% | |
| CD4-positive, alpha-beta T cell | 4 studies | 39% ± 5% | |
| CD8-positive, alpha-beta T cell | 4 studies | 29% ± 7% | |
| deuterosomal cell | 3 studies | 26% ± 1% | |
| epithelial cell | 3 studies | 27% ± 14% | |
| erythroblast | 3 studies | 33% ± 8% |
Insufficient scRNA-seq data for expression of CDC20 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| skin | 93% | 2105.12 | 1686 / 1809 | 93% | 77.55 | 441 / 472 |
| intestine | 52% | 561.49 | 505 / 966 | 96% | 124.41 | 504 / 527 |
| stomach | 48% | 410.55 | 171 / 359 | 96% | 107.23 | 274 / 286 |
| esophagus | 42% | 744.63 | 612 / 1445 | 98% | 106.81 | 179 / 183 |
| lung | 50% | 200.21 | 289 / 578 | 85% | 86.95 | 982 / 1155 |
| bladder | 29% | 48.10 | 6 / 21 | 95% | 136.77 | 480 / 504 |
| breast | 38% | 98.28 | 175 / 459 | 82% | 71.59 | 916 / 1118 |
| uterus | 9% | 27.24 | 15 / 170 | 99% | 188.71 | 454 / 459 |
| ovary | 6% | 35.17 | 11 / 180 | 99% | 138.67 | 424 / 430 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 158.62 | 29 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 211.19 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 72.00 | 1 / 1 |
| spleen | 95% | 934.07 | 230 / 241 | 0% | 0 | 0 / 0 |
| pancreas | 5% | 11.51 | 17 / 328 | 68% | 42.36 | 121 / 178 |
| peripheral blood | 69% | 1751.85 | 643 / 929 | 0% | 0 | 0 / 0 |
| thymus | 47% | 133.07 | 304 / 653 | 17% | 27.17 | 101 / 605 |
| liver | 13% | 71.89 | 29 / 226 | 43% | 27.44 | 175 / 406 |
| adrenal gland | 40% | 99.34 | 103 / 258 | 10% | 6.71 | 24 / 230 |
| kidney | 37% | 185.94 | 33 / 89 | 9% | 4.42 | 78 / 901 |
| brain | 8% | 14.83 | 221 / 2642 | 35% | 24.48 | 246 / 705 |
| adipose | 32% | 89.54 | 383 / 1204 | 0% | 0 | 0 / 0 |
| prostate | 16% | 38.19 | 38 / 245 | 12% | 4.39 | 58 / 502 |
| blood vessel | 10% | 21.85 | 133 / 1335 | 0% | 0 | 0 / 0 |
| heart | 7% | 19.64 | 60 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 6% | 1.54 | 5 / 80 |
| muscle | 1% | 2.28 | 11 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0044784 | Biological process | metaphase/anaphase transition of cell cycle |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0051445 | Biological process | regulation of meiotic cell cycle |
| GO_1990949 | Biological process | metaphase/anaphase transition of meiosis I |
| GO_0031915 | Biological process | positive regulation of synaptic plasticity |
| GO_0045842 | Biological process | positive regulation of mitotic metaphase/anaphase transition |
| GO_0007064 | Biological process | mitotic sister chromatid cohesion |
| GO_0051301 | Biological process | cell division |
| GO_1904668 | Biological process | positive regulation of ubiquitin protein ligase activity |
| GO_0090307 | Biological process | mitotic spindle assembly |
| GO_0031145 | Biological process | anaphase-promoting complex-dependent catabolic process |
| GO_0030154 | Biological process | cell differentiation |
| GO_0007346 | Biological process | regulation of mitotic cell cycle |
| GO_0040020 | Biological process | regulation of meiotic nuclear division |
| GO_0090129 | Biological process | positive regulation of synapse maturation |
| GO_0007399 | Biological process | nervous system development |
| GO_0007094 | Biological process | mitotic spindle assembly checkpoint signaling |
| GO_1905786 | Biological process | positive regulation of anaphase-promoting complex-dependent catabolic process |
| GO_0005680 | Cellular component | anaphase-promoting complex |
| GO_0000922 | Cellular component | spindle pole |
| GO_0005813 | Cellular component | centrosome |
| GO_0000776 | Cellular component | kinetochore |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0033597 | Cellular component | mitotic checkpoint complex |
| GO_0005829 | Cellular component | cytosol |
| GO_0005819 | Cellular component | spindle |
| GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
| GO_1990757 | Molecular function | ubiquitin ligase activator activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0010997 | Molecular function | anaphase-promoting complex binding |
| Gene name | CDC20 |
| Protein name | Cell division cycle protein 20 homolog (p55CDC) |
| Synonyms | |
| Description | FUNCTION: Involved in the metaphase/anaphase transition of cell cycle . Required for full ubiquitin ligase activity of the anaphase promoting complex/cyclosome (APC/C) and may confer substrate specificity upon the complex. Is regulated by MAD2L1: in metaphase the MAD2L1-CDC20-APC/C ternary complex is inactive and in anaphase the CDC20-APC/C binary complex is active in degrading substrates. The CDC20-APC/C complex positively regulates the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. CDC20-APC/C-induced degradation of NEUROD2 induces presynaptic differentiation. The CDC20-APC/C complex promotes proper dilation formation and radial migration by degrading CCDC41 (By similarity). . |
| Accessions | ENST00000310955.11 ENST00000372462.1 Q12834 |
